PHOCUS: A phase 3 randomized, open-label study comparing the oncolytic immunotherapy Pexa-Vec followed by sorafenib (SOR) vs SOR in patients with advanced hepatocellular carcinoma (HCC) without prior systemic therapy Meeting Abstract

  

Authors:	Abou-Alfa, G. K.; Galle, P. R.; Chao, Y.; Brown, K. T.; Heo, J.; Borad, M. J.; Luca, A.; Pelusio, A.; Agathon, D.; Lusky, M.; Breitbach, C.; Burke, J.; Qin, S. K.
Abstract Title:	PHOCUS: A phase 3 randomized, open-label study comparing the oncolytic immunotherapy Pexa-Vec followed by sorafenib (SOR) vs SOR in patients with advanced hepatocellular carcinoma (HCC) without prior systemic therapy
Meeting Title:	52nd Annual Meeting of the American Society of Clinical Oncology (ASCO)
Journal Title:	Journal of Clinical Oncology
Volume:	34
Issue:	15 Suppl.
Meeting Dates:	2016 Jun 3-7
Meeting Location:	Chicago, IL
ISSN:	0732-183X
Publisher:	American Society of Clinical Oncology
Date Published:	2016-05-20
Start Page:	241s
Language:	English
ACCESSION:	WOS:000404665406110
DOI:	10.1200/JCO.2016.34.15_suppl.TPS4146
PROVIDER:	wos
Notes:	Meeting Abstract: TPS4146 -- Source: Wos

https://synapse.mskcc.org/synapse/works/has_related_data_chk/154872